Abstract
4007Background: Hypoxia in PDAC is associated with disease progression and poor prognosis. Evo is a hypoxia-activated prodrug of Br-IPM that is preferentially activated under hypoxic conditions. Th...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have